Jax DiEugenio

Itolizumab Misses Primary End Point in Acute GVHD but Shows Meaningful Improvements in Other Areas

March 27th 2025

The day-29 ORR and CR rate was not met with frontline itolizumab vs placebo in patients with acute graft-vs-host disease enrolled in the phase 3 EQUATOR trial.

Continued Development of T-Cell–Redirecting Therapies Remains at the Heart of Myeloma Research

March 27th 2025

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights advances in T-cell–redirecting therapies in the space.

Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc

March 26th 2025

Drs Park and LaCasce discuss advancements in Hodgkin and non-Hodgkin lymphoma management, including efforts to reduce long-term toxicity.

Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer

March 26th 2025

Dr Paredes on the Association Between Fiber Intake and Improved Survival With Reduced GI aGVHD After Allo-HCT

March 26th 2025

Jenny Paredes, PhD, discusses how increased dietary fiber was associated with improved 24-month survival and reduced lower GI aGVHD in allo-HCT recipients.

Dr Wang on the Role of Menin Inhibitors in Genetically Defined AML Subtypes

March 26th 2025

Eunice S. Wang, MD, discusses the role of menin inhibitors like revumenib in AML with KMT2A rearrangements or NPM1 mutations.

Multiple Myeloma Awareness Month: Symptom Recognition and Understanding Precursor Conditions Are Key for Diagnosis

March 25th 2025

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights symptom recognition and precursor conditions for the malignancy.

Dr Morgans on PSA Doubling Time and Treatment Decisions in Biochemically Recurrent nmHSPC

March 25th 2025

Alicia Morgans, MD, MPH, discusses how a lack of PSA doubling time documentation may lead to undertreatment in high-risk BCR prostate cancer.

Dr Lang on Real-World Safety Data for Perioperative Pembrolizumab in Early TNBC

March 25th 2025

Julie Lang, MD, discusses real-world safety data from for the KEYNOTE-522 regimen in early triple-negative breast cancer.

Low Rates of Late-Onset CAR T-Cell–Related CRS/ICANS Support Shorter AE Monitoring Periods

March 25th 2025

Olalekan O. Oluwole, MD, discusses research findings showing that patients with LBCL may not need prolonged hospital monitoring following axi-cel infusion.

Dr Krishnan on T-Cell Therapies and Novel Targets Reshaping the Myeloma Treatment Landscape

March 25th 2025

Amrita Krishnan, MD, highlights key innovations in multiple myeloma, including GPRC5D-targeted agents and evolving strategies in T-cell–directed therapy.

Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD

March 24th 2025

Xiuning Le, MD, PhD, discusses the HARMONi-2 trial of ivonescimab in patients with advanced PD-L1–positive non–small cell lung cancer.

Reduced Radiotherapy Margins Yield Outcomes Comparable With Standard Margins in HGG

March 24th 2025

A randomized trial found no significant differences in recurrence or survival with smaller radiation margins vs standard RTOG protocols in patients with HGG.

Dr Randall on a Bioengineered Bone Marrow Matrix to Explore Osteosarcoma Progression and Metastasis

March 24th 2025

R. Lor Randall, MD, FACS, discusses the application of a bioengineered bone marrow matrix as a three-dimensional model to analyze osteosarcoma cell behavior under varying oxygen tensions.

Dr Zonder on the Need for Increased Awareness in Multiple Myeloma

March 24th 2025

Jeffrey Zonder, MD, discusses the need for increased awareness in multiple myeloma.

Eribulin and Trabectedin Yield Comparable Real-World OS Outcomes in Advanced Liposarcoma

March 24th 2025

A real-world study showed OS outcomes with eribulin similar to those with trabectedin in doxorubicin-pretreated patients with advanced liposarcoma.

EMA to Review Application for Expanded Indication for Sugemalimab in Unresectable NSCLC

March 24th 2025

A Type II variation application has been submitted to the EMA for the expanded approval of sugemalimab for unresectable stage III NSCLC.

NMPA Approves sNDA for Toripalimab Plus Bevacizumab in Advanced HCC

March 24th 2025

The combination of toripalimab and bevacizumab has been approved in China for the treatment of patients with unresectable or metastatic HCC.

Dr Shah on Zamtocabtagene Autoleucel’s Favorable Safety Profile in R/R DLBCL

March 21st 2025

Zamtocabtagene autoleucel was associated with a manageable safety profile with no grade 3 or higher CRS and low ICANS rates in relapsed/refractory DLBCL.

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Based Insights

March 21st 2025

Joshua Feinberg, MD, discusses the role of the Scout AI platform in aiding trial matching and treatment selection in oncology.